Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LEXX 
Lexaria Bioscience Corp (LEXX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: LEXX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -28.62% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 28.79M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 123191 | Beta 0.96 | 52 Weeks Range 1.15 - 4.44 | Updated Date 04/2/2025 |
52 Weeks Range 1.15 - 4.44 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-04-07 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1462.95% |
Management Effectiveness
Return on Assets (TTM) -67.5% | Return on Equity (TTM) -114.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21325434 | Price to Sales(TTM) 57.93 |
Enterprise Value 21325434 | Price to Sales(TTM) 57.93 | ||
Enterprise Value to Revenue 42.91 | Enterprise Value to EBITDA -7.22 | Shares Outstanding 17552600 | Shares Floating 15690088 |
Shares Outstanding 17552600 | Shares Floating 15690088 | ||
Percent Insiders 7.81 | Percent Institutions 8.21 |
Analyst Ratings
Rating 4 | Target Price 10 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lexaria Bioscience Corp
Company Overview
History and Background
Lexaria Bioscience Corp. was founded in 2004 and has evolved from a nutraceutical company to a biotechnology company focused on drug delivery innovation. Its DehydraTECHu2122 technology is a key milestone, improving the way active pharmaceutical ingredients (APIs) enter the bloodstream.
Core Business Areas
- DehydraTECHu2122 Technology: Lexariau2019s patented drug delivery technology, DehydraTECHu2122, enhances the bioavailability of orally administered drugs, nutraceuticals and consumer products, improving the speed and efficiency of absorption.
- Pharmaceutical Research and Development: Focuses on applying DehydraTECHu2122 to develop pharmaceutical products for cardiovascular disease, hypertension, dementia and nicotine replacement therapy.
Leadership and Structure
Chris Bunka is the CEO of Lexaria Bioscience Corp. The company has a board of directors and an executive team focused on research, development, and commercialization of its DehydraTECHu2122 technology.
Top Products and Market Share
Key Offerings
- DehydraTECHu2122 Technology Licensing: Lexaria licenses its DehydraTECHu2122 technology to other companies for use in their products. The revenue generated from licensing agreements helps fund internal research and development. Competitors in drug delivery technologies include Nanoform, Catalent, and Evonik.
- Pharmaceutical Product Development: Lexaria develops its own pharmaceutical products utilizing the DehydraTECHu2122 platform, specifically targeting hypertension and dementia. Market share is currently not applicable as products are still in development. Competitors in cardiovascular and dementia drugs include large pharmaceutical companies like Pfizer, Novartis, and Roche.
Market Dynamics
Industry Overview
The pharmaceutical industry is experiencing growth in drug delivery technologies that improve bioavailability and efficacy. There is increasing demand for oral drug delivery systems that offer better patient compliance and reduced side effects.
Positioning
Lexaria is positioned as a drug delivery technology innovator with its patented DehydraTECHu2122 platform. Its competitive advantage lies in improved bioavailability, speed of onset, and taste masking.
Total Addressable Market (TAM)
The global drug delivery market is estimated to be worth hundreds of billions of dollars. Lexaria is positioned to capture a portion of this TAM by licensing its technology and developing its own pharmaceutical products. The specific TAM for DehydraTECHu2122 applications within hypertension and dementia represents a significant opportunity.
Upturn SWOT Analysis
Strengths
- Patented DehydraTECHu2122 technology
- Improved bioavailability and efficacy
- Versatile application across multiple industries
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on licensing revenue
- Early stage pharmaceutical development
- Limited product portfolio
Opportunities
- Expanding licensing agreements
- Strategic partnerships with pharmaceutical companies
- Positive clinical trial results
- Growing demand for improved drug delivery systems
Threats
- Competition from established drug delivery companies
- Regulatory hurdles for new drug approvals
- Intellectual property infringement
- Changes in market conditions
Competitors and Market Share
Key Competitors
- Nanoform (NANOF.HE)
- Catalent (CTLT)
- Evonik (EVK.DE)
Competitive Landscape
Lexaria's advantages include its patented DehydraTECHu2122 technology and its focus on improving bioavailability. Disadvantages include limited financial resources and its early stage compared to established competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by technology licensing and research progress.
Future Projections: Future growth is expected to be driven by expanding licensing agreements and advancing pharmaceutical product development.
Recent Initiatives: Recent initiatives include securing new licensing agreements, advancing clinical trials for hypertension and dementia, and exploring new applications for DehydraTECHu2122.
Summary
Lexaria Bioscience is an early-stage biotechnology company with a promising drug delivery technology, DehydraTECHu2122. Its success hinges on expanding licensing agreements and achieving positive clinical trial outcomes. Limited financial resources and competition pose significant challenges. Continued innovation and strategic partnerships are critical for future growth and market penetration.
Similar Companies
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
CTLT
Catalent Inc
CTLT
Catalent Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Lexaria Bioscience Corp. Website
- Company Filings
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share and competitive data are estimates and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexaria Bioscience Corp
Exchange NASDAQ | Headquaters Kelowna, BC, Canada | ||
IPO Launch date 2006-10-10 | CEO & Director Mr. Richard C. Christopher | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://lexariabioscience.com |
Full time employees 7 | Website https://lexariabioscience.com | ||
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.